{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T16:33:24Z","timestamp":1787589204345,"version":"build-2736575974"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejropen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology Open"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ejro.2026.100775","type":"journal-article","created":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T17:06:50Z","timestamp":1781802410000},"page":"100775","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Contrast-enhanced CT based radiomics for prediction of 3-year disease progression in NSCLC patients after anti-PD-1-targeted therapy"],"prefix":"10.1016","volume":"17","author":[{"given":"Wen","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-jia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-ting","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0452-507X","authenticated-orcid":false,"given":"Min","family":"Zong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ejro.2026.100775_bib1","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1097\/CM9.0000000000002108","article-title":"Cancer statistics in China and United States, 2022: profiles, trends, and determinants","volume":"135","author":"Xia","year":"2022","journal-title":"Chin. Med. J. (Engl. )"},{"issue":"5","key":"10.1016\/j.ejro.2026.100775_bib2","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ejro.2026.100775_bib3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41572-024-00551-9","article-title":"Non-small-cell lung cancer","volume":"10","author":"Hendriks","year":"2024","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"10454","key":"10.1016\/j.ejro.2026.100775_bib4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S0140-6736(24)01029-8","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"10.1016\/j.ejro.2026.100775_bib5","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes","volume":"25","author":"Doroshow","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"28","key":"10.1016\/j.ejro.2026.100775_bib6","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-Year Overall Survival for Patients With Advanced Non\u2013Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study","volume":"37","author":"Garon","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"35","key":"10.1016\/j.ejro.2026.100775_bib7","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ejro.2026.100775_bib8","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ejro.2026.100775_bib9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1200\/JCO.21.01497","article-title":"First-Line Immunotherapy for Non-Small-Cell Lung Cancer","volume":"40","author":"Reck","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.ejro.2026.100775_bib10","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1200\/JCO.19.03136","article-title":"Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer","volume":"38","author":"Gadgeel","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ejro.2026.100775_bib11","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ejro.2026.100775_bib12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13244-020-00887-2","article-title":"Radiomics in medical imaging-\"how-to\" guide and critical reflection","volume":"11","author":"van Timmeren","year":"2020","journal-title":"Insights Imaging"},{"issue":"12","key":"10.1016\/j.ejro.2026.100775_bib13","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrclinonc.2017.141","article-title":"Radiomics: the bridge between medical imaging and personalized medicine","volume":"14","author":"Lambin","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ejro.2026.100775_bib14","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1148\/radiol.2021210109","article-title":"Radiomics for Survival Risk Stratification of Clinical and Pathologic Stage IA Pure-Solid Non-Small Cell Lung Cancer","volume":"302","author":"Wang","year":"2022","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.ejro.2026.100775_bib15","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S2589-7500(23)00082-1","article-title":"Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study","volume":"5","author":"Saad","year":"2023","journal-title":"Lancet Digit. Health"},{"issue":"12","key":"10.1016\/j.ejro.2026.100775_bib16","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-24-3791","article-title":"The Society for Immunotherapy of Cancer Perspective on Liquid Biopsy- and Radiomics-Based Technologies for Immuno-oncology Biomarker Discovery and Application","volume":"31","author":"Monette","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejro.2026.100775_bib17","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s00432-025-06119-8","article-title":"An interpretable ensemble model combining handcrafted radiomics and deep learning for predicting the overall survival of hepatocellular carcinoma patients after stereotactic body radiation therapy","volume":"151","author":"Chen","year":"2025","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.ejro.2026.100775_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.105111","article-title":"Transparency of deep neural networks for medical image analysis: A review of interpretability methods","volume":"140","author":"Salahuddin","year":"2022","journal-title":"Comput. Biol. Med."},{"issue":"1","key":"10.1016\/j.ejro.2026.100775_bib19","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/S2213-2600(24)00413-2","article-title":"GOLD COPD report: 2025 update","volume":"13","author":"Venkatesan","year":"2025","journal-title":"Lancet Respir. Med."},{"issue":"3","key":"10.1016\/j.ejro.2026.100775_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032859","article-title":"Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer","volume":"24","author":"Forder","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejro.2026.100775_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1164\/rccm.201704-0795OC","article-title":"Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer","volume":"197","author":"Mark","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.ejro.2026.100775_bib22","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1164\/rccm.201706-1110OC","article-title":"Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade","volume":"198","author":"Biton","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"5","key":"10.1016\/j.ejro.2026.100775_bib23","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.21037\/tlcr-21-214","article-title":"Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors","volume":"10","author":"Zhou","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"7","key":"10.1016\/j.ejro.2026.100775_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16071251","article-title":"Effectiveness of Immunotherapy in Non-Small Cell Lung Cancer Patients with a Diagnosis of COPD: Is This a Hidden Prognosticator for Survival and a Risk Factor for Immune-Related Adverse Events?","volume":"16","author":"Riondino","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ejro.2026.100775_bib25","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jtho.2016.11.2226","article-title":"Radiomic-Based Pathological Response Prediction from Primary Tumors and Lymph Nodes in NSCLC","volume":"12","author":"Coroller","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"5","key":"10.1016\/j.ejro.2026.100775_bib26","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.7150\/thno.48027","article-title":"Assessing PD-L1 expression in non-small cell lung cancer and predicting responses to immune checkpoint inhibitors using deep learning on computed tomography images","volume":"11","author":"Tian","year":"2021","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.ejro.2026.100775_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40644-023-00620-4","article-title":"Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy","volume":"23","author":"Chang","year":"2023","journal-title":"Cancer Imaging"},{"issue":"1","key":"10.1016\/j.ejro.2026.100775_bib28","article-title":"Risk stratification and overall survival prediction in extensive stage small cell lung cancer after chemotherapy with immunotherapy based on CT radiomics","volume":"14","author":"Wang","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ejro.2026.100775_bib29","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.221291","article-title":"CT Radiomics to Predict Macrotrabecular-Massive Subtype and Immune Status in Hepatocellular Carcinoma","volume":"307","author":"Feng","year":"2023","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ejro.2026.100775_bib30","doi-asserted-by":"crossref","first-page":"e222","DOI":"10.1016\/j.crad.2021.12.002","article-title":"Prediction and verification of survival in patients with non-small-cell lung cancer based on an integrated radiomics nomogram","volume":"77","author":"Li","year":"2022","journal-title":"Clin. Radiol."},{"issue":"11","key":"10.1016\/j.ejro.2026.100775_bib31","doi-asserted-by":"crossref","first-page":"7755","DOI":"10.1007\/s00330-022-08859-4","article-title":"CT-based radiomics signature analysis for evaluation of response to induction chemotherapy and progression-free survival in locally advanced hypopharyngeal carcinoma","volume":"32","author":"Liu","year":"2022","journal-title":"Eur. Radiol."},{"issue":"7","key":"10.1016\/j.ejro.2026.100775_bib32","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1007\/s00330-024-11301-6","article-title":"CT-based clinical-radiomics model to predict progression and drive clinical applicability in locally advanced head and neck cancer","volume":"35","author":"Bruixola","year":"2025","journal-title":"Eur. Radiol."},{"issue":"4","key":"10.1016\/j.ejro.2026.100775_bib33","doi-asserted-by":"crossref","DOI":"10.1148\/ryai.2019180075","article-title":"Radiomics Model to Predict Early Progression of Nonmetastatic Nasopharyngeal Carcinoma after Intensity Modulation Radiation Therapy: A Multicenter Study","volume":"1","author":"Du","year":"2019","journal-title":"Radiol. Artif. Intell."}],"container-title":["European Journal of Radiology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352047726000523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352047726000523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:58:23Z","timestamp":1787587103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352047726000523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":33,"alternative-id":["S2352047726000523"],"URL":"https:\/\/doi.org\/10.1016\/j.ejro.2026.100775","relation":{},"ISSN":["2352-0477"],"issn-type":[{"value":"2352-0477","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Contrast-enhanced CT based radiomics for prediction of 3-year disease progression in NSCLC patients after anti-PD-1-targeted therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejro.2026.100775","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100775"}}